In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), with a price target of $62.00. The company’s shares opened today at $13.70.
According to TipRanks, Livshits is a 5-star analyst with an average return of 23.6% and a 39.94% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Meiragtx Holdings, and Rocket Pharmaceuticals.
Rocket Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $46.25.
The company has a one-year high of $36.87 and a one-year low of $7.57. Currently, Rocket Pharmaceuticals has an average volume of 851.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
Read More on RCKT: